Friday 6 November 2026 Export ORKA’s income statement to Excel — free account

Oruka Therapeutics, Inc.

ORKA Healthcare Biotechnology

EPS: −19.6%
Free cash flow: −43.0%

Quarter to June 2026, against a year earlier

102.68 6.66 +6.94%

Follow ORKA

Alert me

Market cap: $6.4B
P/E: 0.0×
Fwd P/E: —
Dividend yield: 0.00%
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Oruka Therapeutics, Inc. 10-K filed Mar 6, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed Mar 6, 2025 · accepted 4:02 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov